AUSTRALIAN BREAST CANCER PATIENTS ENROLLED IN THE LAPATINIB EXPANDED ACCESS PROGRAM (LEAP)

被引：0
|
作者：
Lynch, J. [1 ,2 ]
Boyle, F. [3 ]
Wilkin, N. [4 ]
Hague, C. [5 ]
机构：
[1] St George Hosp, Canc Serv, Kogarah, NSW, Australia
[2] Sutherland Hosp, Canc Serv, Kogarah, NSW, Australia
[3] Mater Hosp, Sydney, NSW, Australia
[4] Westmead Hosp, Westmead, NSW 2145, Australia
[5] Sutherland Hosp, Caringbah, NSW, Australia
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [21] Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases - the UK experience
    Sutherland, S.
    Ashley, S.
    Miles, D.
    Chan, S.
    Wardley, A.
    Davidson, N.
    Bhatti, R.
    Shehata, M.
    Nouras, H.
    Camburn, T.
    Johnston, S. R. D.
    BRITISH JOURNAL OF CANCER, 2010, 102 (06) : 995 - 1002
  • [22] Expanded panel testing in patients with breast or ovarian cancer in a rural familial cancer program
    Hermel, David J.
    McKinnon, Wendy C.
    Colello, Laura
    Greenblatt, Marc S.
    Wood, Marie E.
    CANCER RESEARCH, 2018, 78 (04)
  • [23] Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR+/HER2- Advanced Breast Cancer Enrolled in an Expanded Access Program
    Brufsky, Adam
    Mitra, Debanjali
    Davis, Keith L.
    Nagar, Saurabh P.
    McRoy, Lynn
    Cotter, Matthew J.
    Stearns, Vered
    CLINICAL BREAST CANCER, 2019, 19 (05) : 317 - +
  • [24] Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
    Azeem Saleem
    Graham E Searle
    Laura M Kenny
    Mickael Huiban
    Kasia Kozlowski
    Adam D Waldman
    Laura Woodley
    Carlo Palmieri
    Charles Lowdell
    Tomomi Kaneko
    Philip S Murphy
    Mike R Lau
    Eric O Aboagye
    Raoul C Coombes
    EJNMMI Research, 5
  • [25] Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients
    Koch, Kevin M.
    Im, Young-Hyuck
    Kim, Sung-Bae
    Ribate, Ander Urruticoechea
    Stephenson, Joe
    Botbyl, Jeffrey
    Cartee, Leanne
    Holshouser, Jane
    Ridgway, Derry
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (04): : 336 - 341
  • [26] Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
    Saleem, Azeem
    Searle, Graham E.
    Kenny, Laura M.
    Huiban, Mickael
    Kozlowski, Kasia
    Waldman, Adam D.
    Woodley, Laura
    Palmieri, Carlo
    Lowdell, Charles
    Kaneko, Tomomi
    Murphy, Philip S.
    Lau, Mike R.
    Aboagye, Eric O.
    Coombes, Raoul C.
    EJNMMI RESEARCH, 2015, 5
  • [27] Breast cancer patients enrolled in the Swiss mammography screening program "donna" demonstrate prolonged survival
    Kuklinski, David
    Blum, Marcel
    Subelack, Jonas
    Geissler, Alexander
    Eichenberger, Alena
    Morant, Rudolf
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [28] Baseline characteristics of patients with transthyretin amyloid cardiomyopathy enrolled in a tafamidis expanded access programme
    Rozenbaum, M. H.
    Ionescu, I.
    Clausen, M.
    Lopez, M.
    Sultan, M. B.
    Attal, S.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1799 - 1799
  • [29] Safety profile and tolerability of amprenavir in patients enrolled in an early access program
    Scott, T
    Garris, C
    Rogers, M
    Graham, N
    Garrett, L
    Pedneault, L
    CLINICAL THERAPEUTICS, 2001, 23 (02) : 252 - 259
  • [30] Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program
    van den Eertwegh, Alfonsus J. M.
    Karakiewicz, Pierre
    Bavbek, Sevil
    Rha, Sun Young
    Bracarda, Sergio
    Bahl, Amit
    Ou, Yen-chuan
    Kim, Dennis
    Panneerselvam, Ashok
    Anak, Oezlem
    Gruenwald, Viktor
    UROLOGY, 2013, 81 (01) : 143 - 149
12345